NCT06733987View on ClinicalTrials.gov

Immunological Senescence Phenotype as a Resistance Profile to Pembrolizumab in Patients With Relapsed/Refractory Hodgkin's Lymphoma

RecruitingOBSERVATIONAL

Enrollment

40

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

February 1, 2027

Study Completion Date

February 1, 2027

Conditions

Hodgkin Lymphoma

Trial Locations (1)

40138

RECRUITING

IRCCS Azienda Ospedaliero - Universitaria di Bologna, Bologna

All Listed Sponsors

lead

IRCCS Azienda Ospedaliero-Universitaria di Bologna

OTHER